338 related articles for article (PubMed ID: 9610707)
41. Application of targeted diagnosis of PSMA in the modality shift of prostate cancer diagnosis: a review.
Yan L; Zhang Z; Wang T; Yuan L; Sun X; Su P
Front Oncol; 2023; 13():1179595. PubMed ID: 37727211
[TBL] [Abstract][Full Text] [Related]
42. GRPR versus PSMA: expression profiles during prostate cancer progression demonstrate the added value of GRPR-targeting theranostic approaches.
Verhoeven M; Ruigrok EAM; van Leenders GJLH; van den Brink L; Balcioglu HE; van Weerden WM; Dalm SU
Front Oncol; 2023; 13():1199432. PubMed ID: 37719014
[TBL] [Abstract][Full Text] [Related]
43. [Opportunities for prostate-specific membrane antigen hybrid imaging in prostate cancer].
Strauß AS; Bolenz C; Beer AJ; Zengerling F; Beer M; Miksch J
Urologie; 2023 Nov; 62(11):1153-1159. PubMed ID: 37702749
[TBL] [Abstract][Full Text] [Related]
44. Traditional and novel imaging modalities for advanced prostate cancer: A critical review.
Hill S; Kassam F; Verma S; Sidana A
Urol Ann; 2023; 15(3):249-255. PubMed ID: 37664103
[TBL] [Abstract][Full Text] [Related]
45. Histopathology-validated lesion detection rates of clinically significant prostate cancer with mpMRI, [ 68 Ga]PSMA-11-PET and [ 11 C]Acetate-PET.
Sandgren K; Strandberg SN; Jonsson JH; Grefve J; Keeratijarut Lindberg A; Nilsson E; Bergh A; Söderkvist K; Thellenberg Karlsson C; Friedrich B; Widmark A; Blomqvist L; Berg Loegager V; Axelsson J; Ögren M; Ögren M; Nyholm T; Riklund K
Nucl Med Commun; 2023 Nov; 44(11):997-1004. PubMed ID: 37615497
[TBL] [Abstract][Full Text] [Related]
46. Improved Prostate-Specific Membrane Antigen (PSMA) Stimulation Using a Super Additive Effect of Dutasteride and Lovastatin In Vitro.
Kuzmanov A; Salemi S; Schmid FA; Burger IA; Eberli D; Kranzbühler B
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569712
[TBL] [Abstract][Full Text] [Related]
47. Preclinical Characterization of a Stabilized Gastrin-Releasing Peptide Receptor Antagonist for Targeted Cancer Theranostics.
Abouzayed A; Kanellopoulos P; Gorislav A; Tolmachev V; Maina T; Nock BA; Orlova A
Biomolecules; 2023 Jul; 13(7):. PubMed ID: 37509170
[TBL] [Abstract][Full Text] [Related]
48.
Gade NR; Kaur J; Bhardwaj A; Ebrahimi E; Dufour J; Wuest M; Wuest F
ACS Med Chem Lett; 2023 Jul; 14(7):943-948. PubMed ID: 37465305
[TBL] [Abstract][Full Text] [Related]
49. Synthesis and Evaluation of
Lu K; Zhang C; Zhang Z; Kuo HT; Colpo N; Bénard F; Lin KS
Molecules; 2023 Jun; 28(13):. PubMed ID: 37446782
[TBL] [Abstract][Full Text] [Related]
50. Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer.
Zarrabi KK; Narayan V; Mille PJ; Zibelman MR; Miron B; Bashir B; Kelly WK
Ther Adv Urol; 2023; 15():17562872231182219. PubMed ID: 37359737
[TBL] [Abstract][Full Text] [Related]
51. [Positron emission tomography in oncology].
Czerner CP; Derlin T; Bengel FM; Weiberg D
Radiologie (Heidelb); 2023 Jul; 63(7):549-560. PubMed ID: 37326633
[TBL] [Abstract][Full Text] [Related]
52. Predicting the effect of different folate doses on [
Siebinga H; Hendrikx JJMA; Huitema ADR; de Wit-van der Veen BJ
EJNMMI Res; 2023 Jun; 13(1):60. PubMed ID: 37318681
[TBL] [Abstract][Full Text] [Related]
53. Management of Advanced Prostate Cancer in the Precision Oncology Era.
Gillette CM; Yette GA; Cramer SD; Graham LS
Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37174018
[TBL] [Abstract][Full Text] [Related]
54. Membrane dual-targeting probes: A promising strategy for fluorescence-guided prostate cancer surgery and lymph node metastases detection.
Wu LL; Zhao Q; Wang Q; Zhang Q; Yang F; Zheng B; Hu HY; Xing N
Acta Pharm Sin B; 2023 Mar; 13(3):1204-1215. PubMed ID: 36970202
[TBL] [Abstract][Full Text] [Related]
55. Progression in immunotherapy for advanced prostate cancer.
Liang H; Liu Y; Guo J; Dou M; Zhang X; Hu L; Chen J
Front Oncol; 2023; 13():1126752. PubMed ID: 36925917
[TBL] [Abstract][Full Text] [Related]
56. Comparison of PSMA-based
Wilson ZJ; Xu G; Tewari SO; Lu Y
Am J Nucl Med Mol Imaging; 2023; 13(1):1-10. PubMed ID: 36923600
[TBL] [Abstract][Full Text] [Related]
57. Nanobodies in cell-mediated immunotherapy: On the road to fight cancer.
Maali A; Gholizadeh M; Feghhi-Najafabadi S; Noei A; Seyed-Motahari SS; Mansoori S; Sharifzadeh Z
Front Immunol; 2023; 14():1012841. PubMed ID: 36761751
[TBL] [Abstract][Full Text] [Related]
58. Prostate cancer extracellular vesicle digital scoring assay - a rapid noninvasive approach for quantification of disease-relevant mRNAs.
Wang JJ; Sun N; Lee YT; Kim M; Vagner T; Rohena-Rivera K; Wang Z; Chen Z; Zhang RY; Lee J; Zhang C; Tang H; Widjaja J; Zhang TX; Qi D; Teng PC; Jan YJ; Hou KC; Hamann C; Sandler HM; Daskivich TJ; Luthringer DJ; Bhowmick NA; Pei R; You S; Di Vizio D; Tseng HR; Chen JF; Zhu Y; Posadas EM
Nano Today; 2023 Feb; 48():. PubMed ID: 36711067
[TBL] [Abstract][Full Text] [Related]
59. Halogen Replacement on the Lysine Side Chain of Lys-Urea-Glu-Based PSMA Inhibitors Leads to Significant Changes in Targeting Properties.
Xia L; Liu Y; Cai P; Feng Y; Yuan H; Tang S; Wang YW; Liu N; Chen Y; Zhou Z
Mol Imaging Biol; 2023 Aug; 25(4):765-775. PubMed ID: 36695967
[TBL] [Abstract][Full Text] [Related]
60. PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0.
Fendler WP; Eiber M; Beheshti M; Bomanji J; Calais J; Ceci F; Cho SY; Fanti S; Giesel FL; Goffin K; Haberkorn U; Jacene H; Koo PJ; Kopka K; Krause BJ; Lindenberg L; Marcus C; Mottaghy FM; Oprea-Lager DE; Osborne JR; Piert M; Rowe SP; Schöder H; Wan S; Wester HJ; Hope TA; Herrmann K
Eur J Nucl Med Mol Imaging; 2023 Apr; 50(5):1466-1486. PubMed ID: 36604326
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
